View Item 

Show simple item record

Primary Antifungal Prophylaxis in Adult Hematopoietic Stem Cell Transplant Recipients: Current Therapeutic Concepts

dc.contributor.authorMcCoy, Dorothyen_US
dc.contributor.authorDePestel, Daryl D.en_US
dc.contributor.authorCarver, Peggy L.en_US
dc.date.accessioned2012-03-16T15:57:28Z
dc.date.available2012-03-16T15:57:28Z
dc.date.issued2009-11en_US
dc.identifier.citationMcCoy, Dorothy; DePestel, Daryl D.; Carver, Peggy L. (2009). "Primary Antifungal Prophylaxis in Adult Hematopoietic Stem Cell Transplant Recipients: Current Therapeutic Concepts." Pharmacotherapy: The Journal of Human Pharmacology and Drug Therapy 29(11). <http://hdl.handle.net/2027.42/90237>en_US
dc.identifier.issn0277-0008en_US
dc.identifier.issn1875-9114en_US
dc.identifier.urihttps://hdl.handle.net/2027.42/90237
dc.publisherWiley Periodicals, Inc.en_US
dc.publisherBlackwell Publishing Ltden_US
dc.subject.otherImmunosuppressionen_US
dc.subject.otherProphylaxisen_US
dc.subject.otherAntifungalsen_US
dc.subject.otherInvasive Fungal Infectionen_US
dc.subject.otherIFIen_US
dc.subject.otherHematopoietic Stem Cell Transplanten_US
dc.subject.otherHSCTen_US
dc.subject.otherAzolesen_US
dc.subject.otherEchinocandinsen_US
dc.subject.otherAmphotericin Ben_US
dc.titlePrimary Antifungal Prophylaxis in Adult Hematopoietic Stem Cell Transplant Recipients: Current Therapeutic Conceptsen_US
dc.typeArticleen_US
dc.rights.robotsIndexNoFollowen_US
dc.subject.hlbsecondlevelPharmacy and Pharmacologyen_US
dc.subject.hlbtoplevelHealth Sciencesen_US
dc.description.peerreviewedPeer Revieweden_US
dc.contributor.affiliationumDepartment of Clinical, Social, and Administrative Sciences, College of Pharmacy, University of Michigan Health System, Ann Arbor, Michigan.en_US
dc.contributor.affiliationotherErnest Mario School of Pharmacy, Rutgers, The State University of New Jersey, New Brunswick, New Jersey, and the Department of Infectious Diseases, Hackensack University Medical Center, Hackensack, New Jerseyen_US
dc.description.bitstreamurlhttp://deepblue.lib.umich.edu/bitstream/2027.42/90237/1/phco.29.11.1306.pdf
dc.identifier.doi10.1592/phco.29.11.1306en_US
dc.identifier.sourcePharmacotherapy: The Journal of Human Pharmacology and Drug Therapyen_US
dc.identifier.citedreferenceWolff SN, Fay J, Stevens D, et al. Fluconazole vs low‐dose amphotericin B for the prevention of fungal infections in patients undergoing bone marrow transplantation: a study of the North American marrow transplant group. Bone Marrow Transplant 2000; 25: 853 – 9.en_US
dc.identifier.citedreferenceKrishna G, Martinho M, Chandrasekar P, Ullmann AJ, Patino H. Pharmacokinetics of oral posaconazole in allogeneic hematopoietic stem cell transplant recipients with graft‐versus‐host disease. Pharmacotherapy 2007; 27: 1627 – 36.en_US
dc.identifier.citedreferenceOren I, Rowe JM, Sprecher H, et al. A prospective randomized trial of itraconazole vs fluconazole for the prevention of fungal infections in patients with acute leukemia and hematopoietic stem cell transplant recipients. Bone Marrow Transplant 2006; 38: 127 – 34.en_US
dc.identifier.citedreferenceVan Burik JA, Ratanatharathorn V, Stepan DE, et al. Micafungin versus fluconazole for prophylaxis against invasive fungal infections during neutropenia in patients undergoing hematopoietic stem cell transplantation. Clin Infect Dis 2004; 39: 1407 – 16.en_US
dc.identifier.citedreferenceSlavin MA, Osborne B, Adams R, et al. Efficacy and safety of fluconazole prophylaxis for fungal infections after marrow transplantation: a prospective, randomized, double‐blind study. J Infect Dis 1995; 171: 1545 – 52.en_US
dc.identifier.citedreferenceGoodman JL, Winston DJ, Greenfield RA, et al. A controlled trial of fluconazole to prevent fungal infections in patients undergoing bone marrow transplantation. N Engl J Med 1992; 326: 845 – 51.en_US
dc.identifier.citedreferenceRotstein C, Bow EJ, Laverdiere M, Ioannou S, Carr D, Moghaddam N, for the Canadian Fluconazole Prophylaxis Study Group. Randomized placebo‐controlled trial of fluconazole prophylaxis for neutropenic cancer patients: benefit based on purpose and intensity of cytotoxic therapy. Clin Infect Dis 1999; 28: 331 – 40.en_US
dc.identifier.citedreferenceMenichetti F, Del Favero A, Martino P, et al. Itraconazole oral solution as prophylaxis for fungal infections in neutropenic patients with hematologic malignancies: a randomized, placebo‐controlled, double‐blind, multicenter trial: GIMEMA infection program, gruppo Italiano malattie ematologiche dell‘ adulto. Clin Infect Dis 1999; 28: 250 – 5.en_US
dc.identifier.citedreferenceMacMillan ML, Goodman JL, DeFor TE, Weisdorf DJ. Fluconazole to prevent yeast infections in bone marrow transplantation patients: a randomized trial of high versus reduced dose, and determination of the value of maintenance therapy. Am J Med 2002; 112: 369 – 79.en_US
dc.identifier.citedreferenceKelsey SM, Goldman JM, McCann S, et al. Liposomal amphotericin (AmBisome) in the prophylaxis of fungal infections in neutropenic patients: a randomised, double‐blind, placebo‐controlled study. Bone Marrow Transplant 1999; 23: 163 – 8.en_US
dc.identifier.citedreferencePenack O, Reinwald M, Schmidt‐Hieber M, et al. Low dose liposomal amphotericin B as prophylaxis of invasive fungal infections in patients with prolonged neutropenia: results from a phase III trial [abstract]. In: Program and abstracts of the 45th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2005: M‐975.en_US
dc.identifier.citedreferenceUllmann AJ, Lipton JH, Vesole DH, et al. Posaconazole versus fluconazole for prophylaxis in severe graft‐versus‐host disease. N Engl J Med 2007; 356: 335 – 47.en_US
dc.identifier.citedreferenceKoh LP, Kurup A, Goh YT, Fook‐Chong SM, Tan PH. Randomized trial of fluconazole versus low‐dose amphotericin B in prophylaxis against fungal infections in patients undergoing hematopoietic stem cell transplantation. Am J Hematol 2002; 71: 260 – 7.en_US
dc.identifier.citedreferenceMorgenstern GR, Prentice AG, Prentice HG, Ropner JE, Schey SA, Warnock DW, for the U.K. Multicentre Antifungal Prophylaxis Study Group. A randomized controlled trial of itraconazole versus fluconazole for the prevention of fungal infections in patients with haematological malignancies. Br J Haematol 1999; 105: 901 – 11.en_US
dc.identifier.citedreferenceSchwartz S, Behre G, Heinemann V, et al. Aerosolized amphotericin B inhalations as prophylaxis of invasive aspergillus infections during prolonged neutropenia: results of a prospective randomized multicenter trial. Blood 1999; 93: 3654 – 61.en_US
dc.identifier.citedreferenceTollemar J, Ringden O, Anderson S, et al. Prophylactic use of liposomal amphotericin B (AmBisome) against fungal infections: a randomized trial in bone marrow transplant recipients. Transplant Proc 1993; 25: 1495 – 7.en_US
dc.identifier.citedreferencePerfect JR, Klotman ME, Gilbert CC, et al. Prophylactic intravenous amphotericin B in neutropenic autologous bone marrow transplant recipients. J Infect Dis 1992; 165: 891 – 7.en_US
dc.identifier.citedreferenceEgger T, Gratwohl A, Tichelli A, et al. Comparison of fluconazole with oral polyenes in the prevention of fungal infections in neutropenic patients: a prospective, randomized, single‐center study. Support Care Cancer 1995; 3: 139 – 46.en_US
dc.identifier.citedreferenceHuijgens PC, Simoons‐Smit AM, Van Loenen AC, et al. Fluconazole versus itraconazole for the prevention of fungal infections in hemato‐oncology. J Clin Pathol 1999; 52: 376 – 80.en_US
dc.identifier.citedreferenceNucci M, Biasoli I, Akiti T, et al. A double‐blind, randomized, placebo‐controlled trial of itraconazole capsules as antifungal prophylaxis for neutropenic patients. Clin Infect Dis 2000; 30: 300 – 5.en_US
dc.identifier.citedreferenceRiley DK, Pavia AT, Beatty PG, et al. The prophylactic use of low‐dose amphotericin B in bone marrow transplant patients. Am J Med 1994; 97: 509 – 14.en_US
dc.identifier.citedreferenceWingard JR, Carter SL, Walsh TJ, et al. Results of a randomized, double‐blind trial of fluconazole vs. voriconazole for the prevention of invasive fungal infections in 600 allogeneic blood and marrow transplant patients [abstract]. Blood 2007; 110: abstract 163. Available from http:abstracts.hematologylibrary.orgcgicontentabstractashmtg;11011163maxtoshow&HITS10&hits10&RESULTFORMAT&fulltextvoriconazole&searchid1&FIRSTINDEX0&volume110&issue11&resourcetypeHWCIT&eaf. Accessed October 2, 2008.en_US
dc.identifier.citedreferenceRijnders BJ, Cornelissen JJ, Slobbe L, et al. Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: a randomized, placebo‐controlled trial. Clin Infect Dis 2008; 46: 1401 – 8.en_US
dc.identifier.citedreferenceMarr KA, Seidel K, Slavin MA, et al. Prolonged fluconazole prophylaxis is associated with persistent protection against candidiasis‐related death in allogeneic marrow transplant recipients: long‐term follow‐up of a randomized, placebo‐controlled trial. Blood 2000; 96: 2055 – 61.en_US
dc.identifier.citedreferenceMarr KA, Leisenring W, Crippa F, et al. Cyclophosphamide metabolism is affected by azole antifungals. Blood 2004; 103: 1557 – 9.en_US
dc.identifier.citedreferenceMarks DI, Kibbler C, Pagliuca A, et al. Voriconazole (VOR) vs itraconazole (ITR) for primary prophylaxis of invasive fungal infection (IFI) in allogeneic hematopoietic cell transplant (HCT) recipients [abstract]. In: Program and abstracts of the 49th interscience conference on antimicrobial agents and chemotherapy. Washington, DC: American Society for Microbiology, 2009: M‐1249a.en_US
dc.identifier.citedreferenceClinicalTrials.gov. Identifier NCT00079222. Randomized trial of safety and tolerability of intravenous/oral voriconazole versus intravenous/oral itraconazole for long‐term antifungal prophylaxis in allogeneic hematopoietic stem cell transplant recipients. Available from http:www.clinicaltrials.govct2resultstermvoriconazole. Accessed December 18, 2007.en_US
dc.identifier.citedreferenceO'Sullivan AK, Weinstein MC, Pandya A, et al. Cost‐effectiveness of posaconazole vs fluconazole in the prevention of invasive fungal infections among patients with graft‐versus‐host disease (GVHD) in the U.S. [abstract] Blood 2007; 110: abstract 3336. Available from http:abstracts.hematologylibrary.orgcgicontentabstract110113336maxtoshow&HITS10&hits10&RESULTF0RMAT&fulltextposaconazole&searchid1&FIRSTINDEX0&volume110&issue11&resourcetypeHWCIT. Accessed October 2, 2008.en_US
dc.identifier.citedreferenceMaertens J. Evaluating prophylaxis of invasive fungal infections in patients with haematologic malignancies. Eur J Haematol 2007; 78: 275 – 82.en_US
dc.identifier.citedreferenceEllis ME, Clink H, Ernst P, et al. Controlled study of fluconazole in the prevention of fungal infections in neutropenic patients with haematological malignancies and bone marrow transplant recipients. Eur J Clin Microbiol Infect Dis 1994; 13: 3 – 11.en_US
dc.identifier.citedreferencePhilpott‐Howard JN, Wade JJ, Mufti GJ, Brammer KW, Ehninger G. Randomized comparison of oral fluconazole versus oral polyenes for the prevention of fungal infection in patients at risk of neutropenia. J Antimicrob Chemother 1993; 31: 973 – 84.en_US
dc.identifier.citedreferenceDe La Rosa GR, Champlin RE, Kontoyiannis DP. Risk factors for the development of invasive fungal infections in allogeneic blood and marrow transplant recipients. Transplant Infect Dis 2002; 4: 3 – 9.en_US
dc.identifier.citedreferenceGoodrich JM, Reed EC, Mori M, et al. Clinical features and analysis of risk factors for invasive candidal infection after marrow transplantation. J Infect Dis 1991; 164: 731 – 40.en_US
dc.identifier.citedreferenceMarr KA, Carter RA, Boeckh M, Martin P, Corey L. Invasive aspergillosis in allogeneic stem cell transplant recipients: changes in epidemiology and risk factors. Blood 2002; 100: 4358 – 66.en_US
dc.identifier.citedreferenceJantunen E, Nihtinen A, Anttila VJ. Changing landscape of invasive aspergillosis in allogeneic stem cell transplant recipients. Transpl Infect Dis 2008; 10: 156 – 61.en_US
dc.identifier.citedreferenceBochud PY, Chien JW, Marr KA, et al. Toll‐like receptor 4 polymorphisms and aspergillosis in stem‐cell transplantation. N Engl J Med 2008; 359: 1766 – 77.en_US
dc.identifier.citedreferenceJantunen E, Salonen J, Juvonen E, et al. Invasive fungal infections in autologous stem cell transplant recipients: a nation‐wide study of 1188 transplanted patients. Eur J Haematol 2004; 73: 174 – 8.en_US
dc.identifier.citedreferenceMartino R, Subira M, Rovira M, et al. Invasive fungal infections after allogeneic peripheral blood stem cell transplantation: incidence and risk factors in 395 patients. Br J Haematol 2002; 116: 475 – 82.en_US
dc.identifier.citedreferenceMunoz P, Guinea J, Bouza E. Update on invasive aspergillosis: clinical and diagnostic aspects. Clin Microbiol Infect 2006; 12 ( suppl 7 ): 24 – 39.en_US
dc.identifier.citedreferenceMorgan J, Wannemuehler KA, Marr KA, et al. Incidence of invasive aspergillosis following hematopoietic stem cell and solid organ transplantation: interim results of a prospective multicenter surveillance program. Med Mycol 2005; 43 ( supp 1 ): S49 – 58.en_US
dc.identifier.citedreferenceCenters for Disease Control and Prevention, Infectious Disease Society of America, American Society of Blood and Marrow Transplantation. Guidelines for preventing opportunistic infections among hematopoietic stem cell transplant recipients. MMWR Recomm Rep 2000; 49 ( RR‐10 ): 16.en_US
dc.identifier.citedreferencePlantinga TS, Van Der Velden WJ, Ferwerda B, et al. Early stop polymorphism in human DECTIN‐1 is associated with increased Candida colonization in hematopoietic stem cell transplant recipients. Clin Infect Dis 2009; 49: 724 – 32.en_US
dc.identifier.citedreferenceStrasfeld L, Weinstock DM. Antifungal prophylaxis among allogeneic hematopoietic stem cell transplant recipients: current issues and new agents. Expert Rev Anti Infect Ther 2006; 4: 457 – 68.en_US
dc.identifier.citedreferenceAlexander BD, Schell WA, Miller JL, Long GD, Perfect JR. Candida glabrata fungemia in transplant patients receiving voriconazole after fluconazole. Transplantation 2005; 80: 868 – 71.en_US
dc.identifier.citedreferenceGirmenia C, Moleti ML, Micozzi A, et al. Breakthrough Candida krusei fungemia during fluconazole prophylaxis followed by breakthrough zygomycosis during caspofungin therapy in a patient with severe aplastic anemia who underwent stem cell transplantation. J Clin Microbiol 2005; 43: 5395 – 6.en_US
dc.identifier.citedreferencePavie J, Lacroix C, Hermoso DG, et al. Breakthrough disseminated Aspergillus ustus infection in allogeneic hematopoietic stem cell transplant recipients receiving voriconazole or caspofungin prophylaxis. J Clin Microbiol 2005; 43: 4902 – 4.en_US
dc.identifier.citedreferenceImhof A, Balajee SA, Fredricks DN, Englund JA, Marr KA. Breakthrough fungal infections in stem cell transplant recipients receiving voriconazole. Clin Infect Dis 2004; 39: 743 – 6.en_US
dc.identifier.citedreferenceKontoyiannis DP, Lionakis MS, Lewis RE, et al. Zygomycosis in a tertiary‐care cancer center in the era of Aspergillus ‐active antifungal therapy: a case‐control observational study of 27 recent cases. J Infect Dis 2005; 191: 1350 – 60.en_US
dc.identifier.citedreferenceKauffman CA. Zygomycosis: reemergence of an old pathogen. Clin Infect Dis 2004; 39: 588 – 90.en_US
dc.identifier.citedreferenceMarty FM, Cosimi LA, Baden LR. Breakthrough zygomycosis after voriconazole treatment in recipients of hematopoietic stem‐cell transplants. N Engl J Med 2004; 350: 950 – 2.en_US
dc.identifier.citedreferenceSiwek GT, Dodgson KJ, De Magalhaes‐Silverman M, et al. Invasive zygomycosis in hematopoietic stem cell transplant recipients receiving voriconazole prophylaxis. Clin Infect Dis 2004; 39: 584 – 7.en_US
dc.identifier.citedreferenceVigouroux S, Morin O, Moreau P, et al. Zygomycosis after prolonged use of voriconazole in immunocompromised patients with hematologic disease: attention required. Clin Infect Dis 2005; 40: e35 – 7.en_US
dc.identifier.citedreferenceOrtega M, Rovira M, Almela M, et al. Bacterial and fungal bloodstream isolates from 796 hematopoietic stem cell transplant recipients between 1991 and 2000. Ann Hematol 2005; 84: 40 – 7.en_US
dc.identifier.citedreferenceBaddley JW, Stroud TP, Salzman D, Pappas PG. Invasive mold infections in allogeneic bone marrow transplant recipients. Clin Infect Dis 2001; 32: 1319 – 24.en_US
dc.identifier.citedreferenceMarr KA, Carter RA, Crippa F, Wald A, Corey L. Epidemiology and outcome of mould infections in hematopoietic stem cell transplant recipients. Clin Infect Dis 2002; 34: 909 – 17.en_US
dc.identifier.citedreferenceDe Pauw B, Walsh TJ, Donnelly JP, et al. Revised definitions of invasive fungal disease from the European organization for research and treatment of cancer/invasive fungal infections cooperative group and the national institute of allergy and infectious diseases mycoses study group (EORTC/MSG) consensus group. Clin Infect Dis 2008; 46: 1813 – 21.en_US
dc.identifier.citedreferenceAscioglu S, Rex JH, De Pauw B, et al. Defining opportunistic invasive fungal infections in immunocompromised patients with cancer and hematopoietic stem cell transplants: an international consensus. Clin Infect Dis 2002; 34: 7 – 14.en_US
dc.identifier.citedreferenceHashiguchi K, Niki Y, Soejima R. Cyclophosphamide induces false‐positive results in detection of Aspergillus antigen in urine. Chest 1994; 105: 975 – 6.en_US
dc.identifier.citedreferenceAdam O, Auperin A, Wilquin F, Bourhis JH, Gachot B, Chachaty E. Treatment with piperacillin‐tazobactam and false‐positive Aspergillus galactomannan antigen test results for patients with hematological malignancies. Clin Infect Dis 2004; 38: 917 – 20.en_US
dc.identifier.citedreferenceAshley Dodds E., Lewis R, Lewis JS, Martin C, Andes D. Pharmacology of systemic antifungal agents. Clin Infect Dis 2006; 43: S28 – 39.en_US
dc.identifier.citedreferenceSaad AH, DePestel DD, Carver PL. Factors influencing the magnitude and clinical significance of drug interactions between azole antifungals and select immunosuppressants. Pharmacotherapy 2006; 26: 1730 – 44.en_US
dc.identifier.citedreferenceGoodwin ML, Drew RH. Antifungal serum concentration monitoring: an update. J Antimicrob Chemother 2008; 61: 17 – 25.en_US
dc.identifier.citedreferencePascual A, Calandra T, Bolay S, Buclin T, Bille J, Marchetti O. Voriconazole therapeutic drug monitoring in patients with invasive mycoses improves efficacy and safety outcomes. Clin Infect Dis 2008; 46: 201 – 11.en_US
dc.identifier.citedreferenceWinston DJ, Maziarz RT, Chandrasekar PH, et al. Intravenous and oral itraconazole versus intravenous and oral fluconazole for long‐term antifungal prophylaxis in allogeneic hematopoietic stem‐cell transplant recipients: a multicenter, randomized trial. Ann Intern Med 2003; 138: 705 – 13.en_US
dc.identifier.citedreferenceMarr KA, Crippa F, Leisenring W, et al. Itraconazole versus fluconazole for prevention of fungal infections in patients receiving allogeneic stem cell transplants. Blood 2004; 103: 1527 – 33.en_US
dc.identifier.citedreferenceSmith J, Safdar N, Knasinski V, et al. Voriconazole therapeutic drug monitoring. Antimicrob Agents Chemother 2006; 50: 1570 – 2.en_US
dc.identifier.citedreferenceTrifilio A, Singhal S, Williams S, et al. Breakthrough fungal infections after allogeneic hematopoietic stem cell transplantation in patients on prophylactic voriconazole. Bone Marrow Transplant 2007; 40: 451 – 6.en_US
dc.identifier.citedreferenceImhof A, Schaer DJ, Schwarz U, Schanz U. Neurological adverse events to voriconazole: evidence for therapeutic drug monitoring. Swiss Med Wkly 2006; 136: 739 – 42.en_US
dc.identifier.citedreferenceBrüggemann RJ, Donnelly JP, Aarnoutse RE, et al. Therapeutic drug monitoring of voriconazole. Ther Drug Monit 2008; 30: 403 – 11.en_US
dc.identifier.citedreferenceSurowiec D, DePestel DD, Carver PL. Concurrent administration of sirolimus and voriconazole: a pilot study assessing safety and approaches to appropriate management. Pharmacotherapy 2008; 28: 719 – 29.en_US
dc.identifier.citedreferenceSmith J, Andes D. Therapeutic drug monitoring of antifungals: pharmacokinetic and pharmacodynamic considerations. Ther Drug Monit 2008; 30: 167 – 72.en_US
dc.owningcollnameInterdisciplinary and Peer-Reviewed


Files in this item

Name:
phco.29.11.1306.pdf
Size:
320.2KB
Format:
PDF
View/Open

Show simple item record

Remediation of Harmful Language

The University of Michigan Library aims to describe library materials in a way that respects the people and communities who create, use, and are represented in our collections. Report harmful or offensive language in catalog records, finding aids, or elsewhere in our collections anonymously through our metadata feedback form. More information at Remediation of Harmful Language.

Accessibility

If you are unable to use this file in its current format, please select the Contact Us link and we can modify it to make it more accessible to you.